摘要
慢性阻塞性肺疾病(COPD)是以不完全可逆性气流受限为特征的炎症性疾病,与肺部对香烟烟雾等有害气体或有害颗粒的异常炎症反应有关,同时也存在慢性的全身炎症反应和全身性不良影响,共同影响气流受限的程度和进展。COPD患者体内多种生物标志物明显升高,相关生物标志物的研究,将有助于探索新的干预切入点以及COPD病情评估和治疗反应性监测。
Summary：Chronic obstructive pulmonary disease （COPD） is characterized by the progressive development of airflow limitation that is not fully reversible. The airflow limitation is usually progressive and associated with an abnormal inflammatory response of the lung to noxious particles or gases, especially the cigarette smoking. There is also a chronic systemic inflammatory response and systemic adverse effects ,which affect the degree of airflow limi- tation and disease progression. The pathogenesis of COPD is complex and the chronic inflammation of airway,lung parenchyma and pulmonary blood vessels is considered to be one of the most important mechanisms. A variety of biomarkers were shown to be elevated significantly in COPD patients. The research on biomarkers will be beneficial for exploring new intervention, as well as severity assessment and monitoring of progress and response to treatment in COPD.
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2010年第8期752-754,共3页
Chinese Journal of Practical Internal Medicine
关键词
肺疾病
慢性阻塞性
气道炎症
生物标志物
pulmonary disease, chronic obstructive
pulmonary inflammation
biomarker
作者简介
通讯作者：陈荣昌，电子信箱：chenrc@vip．163．com
